Related Experiment Video
Updated: Jun 7, 2026
A Set of Screening Techniques for a Quick Overview of the Neutrophil Function
Published on: February 9, 2024
N-formyl-methionine-leucine-phenylalanine (fMLP), a Bacterial Chemotactic Peptide, Stimulates Platelet Shape Change
M L Nystrom1, M A Barradas, D P Mikhailidis
1Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School of Medicine (University of London), Pond Street, London, NW3 2QG, UK.
Abstract:
In order to investigate platelet-leucocyte interactions, the effect of N-formyl-methionine-leucine-phenylalonine (fMLP) a bacterial peptide, on platelet shape change (PSC) was studied. fMLP stimulated PSC in human platelets in a dose dependent manner in whole blood but did not cause PSC in platelet rich plasma. Furthermore, PSC induced by fMLP was inhibited by a PAF-antagonist indicating that PAF (a leucocyte release substance) is central to this effect. The present data suggests that PSC in whole blood constitutes a convenient method for the assessment of platelet-leucocyte interactions in health and disease.
Insights
N-formyl-methionine-leucine-phenylalonine (fMLP) triggers platelet shape change in whole blood, not plasma. This interaction, mediated by platelet-activating factor (PAF), offers a method to assess platelet-leucocyte interactions.
Area of Science:
- Hematology
- Immunology
- Biochemistry
Background:
- Platelet-leucocyte interactions are crucial in health and disease.
- N-formyl-methionine-leucine-phenylalonine (fMLP), a bacterial peptide, is known to interact with immune cells.
- Platelet shape change (PSC) is a measurable indicator of platelet activation.
Purpose of the Study:
- To investigate the effect of fMLP on platelet shape change (PSC).
- To explore the role of platelet-activating factor (PAF) in fMLP-induced PSC.
- To establish a method for assessing platelet-leucocyte interactions.
Main Methods:
- Studied the effect of fMLP on human platelets in whole blood and platelet-rich plasma.
- Assessed PSC in a dose-dependent manner.
- Utilized a PAF-antagonist to investigate the role of PAF.
Main Results:
- fMLP stimulated PSC in human platelets in a dose-dependent manner in whole blood.
- fMLP did not induce PSC in platelet-rich plasma.
- PSC induced by fMLP was inhibited by a PAF-antagonist, indicating PAF's central role.
Conclusions:
- fMLP-induced PSC in whole blood is dependent on leucocytes and mediated by PAF.
- PSC in whole blood is a convenient method for assessing platelet-leucocyte interactions.
- This method can be applied to study platelet-leucocyte interactions in various health and disease states.
